Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myosin XVI (MYO16) is an unconventional, neuronally expressed myosin that binds actin filaments and plays a specific role in the regulation of actin cytoskeleton dynamics particularly in dendritic spines of neurons[1][2]. It contains an N-terminal ankyrin repeat domain that interacts with protein phosphatase 1 catalytic subunits, a myosin motor domain (likely with impaired ATPase activity), and a tail region that interacts with both phosphoinositide 3-kinase (PI3K) and the WAVE regulatory complex (WRC), thereby functioning as an adaptor linking signaling complexes that control actin polymerization[1]. MYO16 is critical for normal presynaptic organization in the cerebellum and may regulate neuronal morphogenesis by activating PI3K and recruiting the WAVE1 complex[1][2]. Genetic variants are linked with risk for neuropsychiatric disorders including schizophrenia and autism spectrum disorder, and upregulation of MYO16 has been observed in the frontal cortex of schizophrenia patients[2]. This protein does not serve as a typical receptor, enzyme, or known direct therapeutic target, and no interacting drugs or disease biomarkers are established at this time[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Myosin XVI (MYO16).